U.S. health regulators on Friday approved a Celgene Corporation (NASDAQ:CELG) drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling. Celgene Corporation (NASDAQ:CELG) stock performance was -3.74% in last session and finished the day at $144.40. Traded volume was 9.50million shares in the last session and the average volume of the stock remained … Continue reading Biotech Active Stocks: Celgene Corporation (NASDAQ:CELG), Arena Pharmaceuticals (NASDAQ:ARNA), Cell Therapeutics (NASDAQ:CTIC), Inovio Pharmaceuticals (NYSEMKT:INO)